6645.TW Kim Forest Enterprise Co., Ltd.
- Market cap
- TWD 770M
- P/E
- -
- P/B
- 1.84x
- ROE
- -36.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6645.TW undervalued?
Graham numberThe Graham number of Kim Forest Enterprise Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kim Forest Enterprise Co., Ltd. fundamental analysis
No fundamental analysis for Kim Forest Enterprise Co., Ltd. yet.
Kim Forest Enterprise Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kim Forest Enterprise Co., Ltd.
Kim Forest Enterprise Co., Ltd. provides various genetic and medical testing services in China and the United States. The company provides genetic testing, drug report, and monitoring tools for cancer patients; and GoL Life that provides a non-invasive genome-wide health assessment for healthy persons. It offers bioinformatics service items; prenatal test kits; and genetically modified models. In addition, the company offers SARS-CoV-2 detection kits. Further, it engages in …
Full company profileKim Forest Enterprise Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kim Forest Enterprise Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 262M | 264M | 232M | 271M | 303M | 601M | 671M | 415M | 502M | 549M | 557M |
| Gross Profit | 58.8M | 70.9M | 44.9M | 51.6M | 79.3M | 259M | 254M | 78.6M | 56.2M | 71.8M | 83.3M |
| Operating Income | 9.20M | 11.4M | -35.8M | -40.4M | -33.3M | 113M | 73.1M | -126M | -171M | -142M | -154M |
| EBITDA | 17.2M | 18.4M | -25.2M | -23.3M | -15.6M | 141M | 110M | -72.7M | -103M | -74.3M | -78.8M |
| Net Income | 9.55M | 8.83M | -30.7M | -31.9M | -26.2M | 89.4M | 42.4M | -102M | -160M | -146M | -153M |
| EPS | 0.41 | 0.29 | -0.89 | -0.95 | -0.60 | 1.79 | 0.86 | -2.11 | -2.96 | -2.41 | -2.52 |
| Balance Sheet | |||||||||||
| Total Assets | 325M | 463M | 517M | 504M | 594M | 743M | 847M | 970M | 1.14B | 1.02B | 1.04B |
| Total Liabilities | 172M | 188M | 278M | 297M | 143M | 201M | 265M | 392M | 503M | 504M | 604M |
| Shareholders' Equity | 153M | 274M | 239M | 207M | 451M | 542M | 582M | 578M | 636M | 491M | 419M |
| Cash & Short-term Investments | 38.5M | 46.4M | 57.5M | 26.7M | 86.6M | 181M | 125M | 187M | 218M | 124M | 101M |
| Total Debt | 124M | 129M | 214M | 231M | 52.4M | 106M | 131M | 219M | 367M | 386M | 473M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 17.1M | -44.1M | -8.32M | -21.5M | -24.7M | 89.7M | 53.0M | -64.5M | -171M | -56.6M | -150M |
| Capital Expenditure | 1.82M | 67.2M | 57.4M | 8.41M | 463K | 8.71M | 110M | 36.8M | 99.5M | 57.8M | 40.2M |
| Free Cash Flow | 15.3M | -111M | -65.7M | -29.9M | -25.2M | 81.0M | -57.4M | -101M | -270M | -114M | -175M |
| Ratios | |||||||||||
| ROE | 6.2% | 3.2% | -12.9% | -15.4% | -5.8% | 16.5% | 7.3% | -17.7% | -25.1% | -29.8% | -36.4% |
| ROA | 2.9% | 1.9% | -5.9% | -6.3% | -4.4% | 12.0% | 5.0% | -10.6% | -14.0% | -14.4% | -14.6% |
| Net Profit Margin | 3.6% | 3.3% | -13.3% | -11.8% | -8.6% | 14.9% | 6.3% | -24.7% | -31.9% | -26.7% | -27.4% |
| Debt to Equity | 0.81x | 0.47x | 0.90x | 1.11x | 0.12x | 0.20x | 0.22x | 0.38x | 0.58x | 0.79x | 1.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kim Forest Enterprise Co., Ltd. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 20, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | TWD 4.03M | 0.08 | - |
| 2022 | TWD 7.75M | 0.16 | 18.3% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | 3.97M | 0.11 | - |
| 2017 | 806K | 0.03 | 9.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1050:1000 on Jul 16, 2024.
Who owns Kim Forest Enterprise Co., Ltd.
Ownership data of Kim Forest Enterprise Co., Ltd. is not available yet.
Kim Forest Enterprise Co., Ltd. company profile
- Company name
- Kim Forest Enterprise Co., Ltd.
- Ticker
- 6645.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Fiscal year end
- December
- Address
- No. 97, Xintai 5th Road, New Taipei City, Taiwan, 22175
- Phone
- 886 2 2790 2222
- Website
- kimforest.com
About Kim Forest Enterprise Co., Ltd.
Kim Forest Enterprise Co., Ltd. provides various genetic and medical testing services in China and the United States. The company provides genetic testing, drug report, and monitoring tools for cancer patients; and GoL Life that provides a non-invasive genome-wide health assessment for healthy persons. It offers bioinformatics service items; prenatal test kits; and genetically modified models. In addition, the company offers SARS-CoV-2 detection kits. Further, it engages in the wholesale of medical instruments and consumables; and provision of various genetic and medical testing services. The company was founded in 2004 and is headquartered in New Taipei City, Taiwan.
Kim Forest Enterprise Co., Ltd. management
5- Daniel HuangChief Executive officer
- Xiuping ChenFinance Manager
- Qian Qi LinAccounting Supervisor
- Ming Xi XiaoChief Research and Development Officer
- Wen Lan XuHead of Corporate Governance